Kynam Capital reports 6.78% stake in Celldex
Kynam Capital Management, LP, together with Kynam Capital Management GP, LLC and Yue Tang, reports beneficial ownership of Celldex Therapeutics, Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kynam Capital Management, LP, together with Kynam Capital Management GP, LLC and Yue Tang, reports beneficial ownership of Celldex Therapeutics, Inc. common stock. The group has shared voting and dispositive power over 5,322,908 shares, representing 6.78% of Celldex’s outstanding common stock, with no sole voting or dispositive power reported for any of the filers.
Key Figures
Key Terms
beneficially owned financial
percent of class financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Celldex Therapeutics (CLDX) does Kynam Capital report owning?
Who are the reporting persons in this Celldex (CLDX) ownership filing?
What class of Celldex (CLDX) securities is reported as owned by Kynam Capital?
AI-generated analysis. How Rhea-AI works. Not financial advice.